PUBLIC COMPANY
saveSHIONOGI
USupdated 1mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease
- phase1A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
- phase3A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19
- phase2An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD)
- phase2A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
- phase2A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
- phase3Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
- phase2Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke
🐶 Hiring Signal
News
- Shionogi's stroke drug fails mid-stage; Bayer's Hyrnuo gets expanded labelPlus news about Tevard Biosciences, InduPro, EMD Serono, Shionogi, Bayer's Hyrnuo. Disc's competitor for Takeda's blood disorder drug Mimrylo: Disc Medicine shared initial data from its Phase 2 RES…endpoints · 5d ago
- Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOsSanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.biopharma_dive · 1mo ago
- Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launchApnimed has raised $192 million for its upsized IPO, with the proceeds earmarked to fund the launch of its sleep apnea pill.fiercebiotech · 1mo ago
- Antifungal from F2G, Shionogi succeeds in Phase 3 studyF2G and Shionogi released positive Phase 3 data on Thursday morning, giving the companies a potentially clear path to approval for their antifungal drug. The companies said their treatment called o…endpoints · 2mo ago
- Shionogi wins US approval for first pill to prevent Covid following exposureJapan's Shionogi on Monday said it won FDA approval for its oral antiviral to prevent Covid‑19 in adults and children older than 12 years who have been in contact with someone ...endpoints · 3mo ago
comments(0)
5-min edit window · permanent after that